Regimen for treating prostate tissue and surgical kit for use in the regimen

Abstract

The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.

1 . A treatment regimen for treating a prostate disease comprising: 
 a) chemically ablating prostate tissue sufficiently to elicit a reparative process; and    b) coadministering a therapeutically effective amount of an antiandrogen;    such that steps a) and b) are sufficient to reduce the size of the prostate relative to its size prior to treatment.    
   
   
       2 . The treatment regimen of  claim 1  wherein the disease is benign prostatic hyperplasia.  
   
   
       3 . The treatment regimen of  claim 1  wherein the disease is prostatic carcinoma.  
   
   
       4 . The treatment regimen of  claim 1  wherein chemically ablating includes injecting ethanol into a portion of prostate tissue.  
   
   
       5 . The treatment regimen of  claim 4  wherein ethanol is injected transurethrally.  
   
   
       6 . The treatment regimen of  claim 4  wherein ethanol is injected in the form of an injectable gel.  
   
   
       7 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen includes administering a non-steroidal antiandrogen.  
   
   
       8 . The treatment regimen of  claim 7  wherein the non-steroidal antiandrogen is selected from the group consisting of flutamide, nilutamide and bicalutamide.  
   
   
       9 . The treatment regimen of  claim 7  wherein the non-steroidal antiandrogen comprises bicalutamide.  
   
   
       10 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen includes administering a steroidal antiandrogen.  
   
   
       11 . The treatment regimen of  claim 10  wherein the steroidal antiandrogen is selected from the group consisting of cyproterone acetate, megestrol acetate, medroxyprogesterone acetate, chlormadinone acetate, and WIN 49596.  
   
   
       12 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen occurs after chemically ablating the prostate tissue.  
   
   
       13 . The treatment regimen of  claim 1  wherein at least part of the step of coadministering an antiandrogen occurs prior to chemically ablating the prostate tissue.  
   
   
       14 . The treatment regimen of  claim 1  wherein at least part of the step of coadministering an antiandrogen occurs substantially during the step of chemically ablating the prostate tissue.  
   
   
       15 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen further includes administering a luteinizing hormone-releasing hormone analog.  
   
   
       16 . The treatment regimen of  claim 15  wherein the luteinizing hormone-releasing hormone analog is selected from the group consisting of leuprolide acetate, goserelin acetate, buserelin acetate, and triptorelin pamoate.  
   
   
       17 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen further includes administering a luteinizing hormone-releasing hormone antagonist.  
   
   
       18 . The treatment regimen of  claim 17  wherein the luteinizing hormone-releasing hormone antagonist is selected from the group consisting of cetrorelix and abarelix.  
   
   
       19 . The treatment regimen of  claim 1  wherein coadministering an antiandrogen further includes administering an inhibitor of 5α-reductase.  
   
   
       20 . The treatment regimen of  claim 19  wherein the inhibitor of 5α-reductase effectively inhibits Type II 5□-reductase.  
   
   
       21 . The treatment regimen of  claim 19  wherein coadministering an inhibitor of 5α-reductase includes administering a synthetic 4-azasteroid compound.  
   
   
       22 . The treatment regimen of  claim 21  wherein the 4-azasteroid compound is selected from the group consisting of finasteride, dutasteride and PNU 157706.  
   
   
       23 . A treatment regimen for treating a prostate disease comprising: 
 a) injecting an effective amount of ethanol into prostate tissue to ablate a significant amount of prostate tissue; and    b) coadministering a therapeutically effective amount of an antiandrogen; such that steps a) and b) are sufficient to reduce the size of the prostate relative to its size prior to treatment.    
   
   
       24 . The treatment regimen of  claim 23  wherein the disease is benign prostatic hyperplasia.  
   
   
       25 . The treatment regimen of  claim 23  wherein the disease is prostatic carcinoma.  
   
   
       26 . The treatment regimen of  claim 23  wherein the ethanol is injected into the prostate tissue transurethrally.  
   
   
       27 . The treatment regimen of  claim 23  wherein ethanol is injected in the form of an injectable gel.  
   
   
       28 . The treatment regimen of  claim 23  wherein coadministering an antiandrogen includes administering a non-steroidal antiandrogen.  
   
   
       29 . The treatment regimen of  claim 28  wherein the non-steroidal antiandrogen is selected from the group consisting of flutamide, nilutamide and bicalutamide.  
   
   
       30 . The treatment regimen of  claim 28  wherein the non-steroidal antiandrogen comprises bicalutamide.  
   
   
       31 . The treatment regimen of  claim 23  wherein coadministering an antiandrogen includes administering a steroidal antiandrogen.  
   
   
       32 . The treatment regimen of  claim 31  wherein the steroidal antiandrogen is selected from the group consisting of cyproterone acetate, megestrol acetate, medroxyprogesterone acetate, chlormadinone acetate, and WIN 49596.  
   
   
       33 . The treatment regimen of  claim 23  wherein coadministering an antiandrogen occurs after ablating the prostate tissue.  
   
   
       34 . The treatment regimen of  claim 23  wherein at least part of the step of coadministering an antiandrogen occurs prior to ablating the prostate tissue.  
   
   
       35 . The treatment regimen of  claim 23  wherein at least part of the step of coadministering an antiandrogen occurs substantially during the step of ablating the prostate tissue.